- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Central precocious puberty Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 349KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 73KB)
Leuprorelin – November 2024
Leuprorelin; Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 7.5 mg, injection set, Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 22.5 mg, injection set, Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 30 mg, injection set, Suspension for subcutaneous injection (modified release) containing leuprorelin acetate 45 mg, injection set; Eligard®
Last updated
30 May 2025
